ATS
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Personal Folders
Right arrow Download to citation manager
Right arrow Author home page(s):
Peter K. Smith
Right arrow Permission Requests
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lincoff, A. M.
Right arrow Articles by Topol, E. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lincoff, A. M.
Right arrow Articles by Topol, E. J.

Ann Thorac Surg 2000;70:516-526
© 2000 The Society of Thoracic Surgeons

Original articles: cardiovascular

Abciximab and bleeding during coronary surgery: results from the EPILOG and EPISTENT trials*

A. Michael Lincoff, MDa, LeRoy A. LeNarz, MDc, George J. Despotis, MDd, Peter K. Smith, MDe, Joan E. Booth, RNa, Russell E. Raymond, DOa, Shelly K. Sapp, MSb, Catherine F. Cabot, MDg, James E. Tcheng, MDf, Robert M. Califf, MDf, Mark B. Effron, MDc, Eric J. Topol, MDa, EPILOG and EPISTENT Investigators

a Department of Cardiology, Cleveland Clinic Foundation, Cleveland, Ohio, USA
b Department of Biostatistics, Cleveland Clinic Foundation, Cleveland, Ohio, USA
c Eli Lilly and Company, Indianapolis, Indiana, USA
d Department of Anesthesiology, Washington University School of Medicine, St. Louis, Missouri, USA
e Division of Thoracic Surgery, Duke University Medical Center, Durham, North Carolina, USA
f Duke Clinical Research Institute, Duke University Medical Center, Durham, North Carolina, USA
g Centocor, Malvern, Pennsylvania, USA

Address reprint requests to Dr Lincoff, Department of Cardiology, Desk F25, The Cleveland Clinic Foundation, 9500 Euclid Ave, Cleveland, OH 44195

Background. Abciximab during percutaneous coronary revascularization reduces ischemic complications, but concern exists regarding increased bleeding risk should emergency coronary surgical procedures be required.

Methods. Outcomes were assessed among 85 patients who required coronary artery bypass grafting operations after coronary intervention in two randomized placebo-controlled trials of abciximab. Comparisons were made between patients in the pooled placebo and abciximab groups.

Results. The incidence of coronary surgical procedures was 2.17% and 1.28% among patients randomized to placebo and abciximab, respectively (p = 0.021). Platelet transfusions were administered to 32% and 52% of patients in the placebo and abciximab groups, respectively (p = 0.059). Rates of major blood loss were 79% and 88% in the placebo and abciximab groups, respectively (p = 0.27); transfusions of packed red blood cells or whole blood were administered in 74% and 80% of patients, respectively (p = 0.53). Surgical reexploration for bleeding was required in 3% and 12% of patients, respectively. Death and myocardial infarction tended to occur less frequently among patients who had received abciximab.

Conclusions. Urgent coronary artery bypass grafting operations can be performed without an incremental increase in major hemorrhagic risk among patients on abciximab therapy.




This article has been cited by other articles:


Home page
 J CARDIOVASC PHARMACOL THERHome page
C. M. Dyke, L. K. Jennings, G. Maier, C. Andreou, R. Daly, and M. R. Tamberella III
Preoperative Platelet Inhibition With Eptifibatide During Coronary Artery Bypass Grafting With Cardiopulmonary Bypass
Journal of Cardiovascular Pharmacology and Therapeutics, March 1, 2007; 12(1): 54 - 60.
[Abstract] [PDF]

Home page
 Canadian J. AnesthesiaHome page
T. Lecompte and J.-F. Hardy
Antiplatelet agents and perioperative bleeding: [Les inhibiteurs plaquettaires et le saignement perioperatoire].
Can J Anesth, June 1, 2006; 53(6_suppl): S103 - S112.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Thorac. Surg.Home page
C. K. Haan, S. O'Brien, F. H. Edwards, E. D. Peterson, and T. B. Ferguson
Trends in emergency coronary artery bypass grafting after percutaneous coronary intervention, 1994-2003.
Ann. Thorac. Surg., May 1, 2006; 81(5): 1658 - 1665.
[Abstract] [Full Text] [PDF]

Home page
 J Am Coll CardiolHome page
R. Glaser, H. A. Glick, H. C. Herrmann, and S. E. Kimmel
The Role of Risk Stratification in the Decision to Provide Upstream Versus Selective Glycoprotein IIb/IIIa Inhibitors for Acute Coronary Syndromes: A Cost-Effectiveness Analysis
J. Am. Coll. Cardiol., February 7, 2006; 47(3): 529 - 537.
[Abstract] [Full Text] [PDF]

Home page
 SEMIN CARDIOTHORAC VASC ANESTHHome page
A. Shander, D. Moskowitz, and T. S. Rijhwani
The Safety and Efficacy of "Bloodless" Cardiac Surgery
Seminars in Cardiothoracic and Vascular Anesthesia, March 1, 2005; 9(1): 53 - 63.
[Abstract] [PDF]

Home page
 J Am Coll CardiolHome page
Committee Members, K. A. Eagle, R. A. Guyton, R. Davidoff, F. H. Edwards, G. A. Ewy, T. J. Gardner, J. C. Hart, H. C. Herrmann, L. D. Hillis, et al.
ACC/AHA 2004 guideline update for coronary artery bypass graft surgery: Summary article: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Update the 1999 Guidelines for Coronary Artery Bypass Graft Surgery)
J. Am. Coll. Cardiol., September 1, 2004; 44(5): 1146 - 1154.
[Full Text] [PDF]

Home page
 CirculationHome page
K. A. Eagle, R. A. Guyton, R. Davidoff, F. H. Edwards, G. A. Ewy, T. J. Gardner, J. C. Hart, H. C. Herrmann, L. D. Hillis, A. M. Hutter Jr, et al.
ACC/AHA 2004 Guideline Update for Coronary Artery Bypass Graft Surgery: Summary Article: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Update the 1999 Guidelines for Coronary Artery Bypass Graft Surgery)
Circulation, August 31, 2004; 110(9): 1168 - 1176.
[Full Text] [PDF]

Home page
 SEMIN CARDIOTHORAC VASC ANESTHHome page
M. B. Vroom
Epidemiology and Pharmacotherapy of Acute Heart Failure
Seminars in Cardiothoracic and Vascular Anesthesia, March 1, 2003; 7(1): 3 - 12.
[PDF]

Home page
 J Am Coll CardiolHome page
R. H. Hongo, J. Ley, S. E. Dick, and R. R. Yee
The effect of clopidogrel incombination with aspirin whengiven before coronary artery bypass grafting
J. Am. Coll. Cardiol., July 17, 2002; 40(2): 231 - 237.
[Abstract] [Full Text] [PDF]

Home page
 J Am Coll CardiolHome page
M. Singh, H. H. Ting, P. B. Berger, K. N. Garratt, D. R. Holmes Jr, and B. J. Gersh
Rationale for on-site cardiac surgery for primary angioplasty: a time for reappraisal
J. Am. Coll. Cardiol., June 19, 2002; 39(12): 1881 - 1889.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Thorac. Surg.Home page
G. J. Despotis, M. S. Avidan, and C. W. Hogue Jr
Mechanisms and attenuation of hemostatic activation during extracorporeal circulation
Ann. Thorac. Surg., November 1, 2001; 72(5): S1821 - 1831.
[Abstract] [Full Text] [PDF]

Home page
 SEMIN CARDIOTHORAC VASC ANESTHHome page
N. J. Skubas and G. J. Despotis
Optimal Management of Bleeding Complications After Cardiac Surgery
Seminars in Cardiothoracic and Vascular Anesthesia, September 1, 2001; 5(3): 217 - 228.
[Abstract] [PDF]

Home page
 Ann. Thorac. Surg.Home page
G. J. Despotis and L. T. Goodnough
Management approaches to platelet-related microvascular bleeding in cardiothoracic surgery
Ann. Thorac. Surg., August 1, 2000; 70(2): S20 - 32.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Thorac. Surg.Home page
L. H. Edmunds Jr
The quill passes
Ann. Thorac. Surg., July 1, 2000; 70(1): 1 - 2.
[Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
ANN THORAC SURG ASIAN CARDIOVASC THORAC ANN EUR J CARDIOTHORAC SURG
J THORAC CARDIOVASC SURG ICVTS ALL CTSNet JOURNALS
Copyright © 2000 by The Society of Thoracic Surgeons.